Trial Profile
Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Biomarker; Pharmacodynamics
- 18 Mar 2024 Status changed from active, no longer recruiting to completed.
- 16 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 16 Dec 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.